Modelling of primary ciliary dyskinesia using patient-derived airway organoids.
Jelte van der VaartLena BöttingerMaarten H GeurtsWilline J van de WeteringKèvin KnoopsNorman SachsHarry BegthelJeroen KorvingCarmen Lopez-IglesiasPeter J PetersKerem EitanAlex Gileles-HillelHans CleversPublished in: EMBO reports (2021)
Patient-derived human organoids can be used to model a variety of diseases. Recently, we described conditions for long-term expansion of human airway organoids (AOs) directly from healthy individuals and patients. Here, we first optimize differentiation of AOs towards ciliated cells. After differentiation of the AOs towards ciliated cells, these can be studied for weeks. When returned to expansion conditions, the organoids readily resume their growth. We apply this condition to AOs established from nasal inferior turbinate brush samples of patients suffering from primary ciliary dyskinesia (PCD), a pulmonary disease caused by dysfunction of the motile cilia in the airways. Patient-specific differences in ciliary beating are observed and are in agreement with the patients' genetic mutations. More detailed organoid ciliary phenotypes can thus be documented in addition to the standard diagnostic procedure. Additionally, using genetic editing tools, we show that a patient-specific mutation can be repaired. This study demonstrates the utility of organoid technology for investigating hereditary airway diseases such as PCD.
Keyphrases
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- endothelial cells
- peritoneal dialysis
- prognostic factors
- induced pluripotent stem cells
- induced apoptosis
- pulmonary hypertension
- crispr cas
- genome wide
- patient reported outcomes
- gene expression
- signaling pathway
- patient reported
- cystic fibrosis
- dna methylation
- minimally invasive
- cell cycle arrest
- endoplasmic reticulum stress